{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023968","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.687791+00:00","generated_at":"2026-05-17T13:16:19.026072+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Co-Diagnostics Q2 revenue falls to $0.2M from $2.7M; net loss $7.7M","bullets":["Revenue $0.2M vs $2.7M in Q2 2024; no grant revenue recognized in Q2 2025.","Operating loss $8.1M vs $7.7M prior year; expenses down 19.1% to $8.2M.","Net loss $7.7M ($0.23 per share) vs $7.6M ($0.25 per share) in Q2 2024.","Cash & marketable securities $13.4M as of June 30, 2025; adjusted EBITDA loss $7.2M.","On track to initiate clinical evaluations for Co-Dx PCR platform tests before year-end; enhanced COVID-19 test trial starting imminently."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023968","json":"https://secwatch.observer/filing/0001641172-25-023968.json","markdown":"https://secwatch.observer/filing/0001641172-25-023968.md","text":"https://secwatch.observer/filing/0001641172-25-023968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/0001641172-25-023968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:16:19.026072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}